In April and May, the European Commission authorized two biosimilars of eculizumab, the medication indicated for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria.
Industry news
In April and May, the European Commission authorized two biosimilars of eculizumab, the medication indicated for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria.
recently published
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.